Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Current Leases (2021 - 2025)

Historic Current Leases for ARS Pharmaceuticals (SPRY) over the last 5 years, with Q3 2025 value amounting to $583000.0.

  • ARS Pharmaceuticals' Current Leases rose 47156.86% to $583000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $583000.0, marking a year-over-year increase of 47156.86%. This contributed to the annual value of $42000.0 for FY2024, which is 8227.85% down from last year.
  • According to the latest figures from Q3 2025, ARS Pharmaceuticals' Current Leases is $583000.0, which was up 47156.86% from $589000.0 recorded in Q2 2025.
  • In the past 5 years, ARS Pharmaceuticals' Current Leases ranged from a high of $1.1 million in Q1 2022 and a low of $42000.0 during Q4 2024
  • For the 5-year period, ARS Pharmaceuticals' Current Leases averaged around $435315.8, with its median value being $233000.0 (2023).
  • In the last 5 years, ARS Pharmaceuticals' Current Leases tumbled by 8227.85% in 2024 and then soared by 47156.86% in 2025.
  • Quarter analysis of 5 years shows ARS Pharmaceuticals' Current Leases stood at $144000.0 in 2021, then surged by 59.72% to $230000.0 in 2022, then rose by 3.04% to $237000.0 in 2023, then plummeted by 82.28% to $42000.0 in 2024, then soared by 1288.1% to $583000.0 in 2025.
  • Its last three reported values are $583000.0 in Q3 2025, $589000.0 for Q2 2025, and $73000.0 during Q1 2025.